Why will it never be known if convalescent plasma is effective for COVID-19

Manuel Rojas; Juan Manuel Anaya

doi:10.1016/j.jtauto.2020.100069

Why will it never be known if convalescent plasma is effective for COVID-19

Manuel Rojas
, Juan Manuel Anaya

Research output: Contribution to Journal › Review article › peer-review

15 Scopus citations

Abstract

High expectations have been set around convalescent plasma (CP) for the treatment of COVID-19. However, none of the randomized controlled trials (RCTs) conducted so far have reached their primary endpoints. Herein we report that RCTs of CP disclose a high methodological variability in inclusion criteria, outcomes, appropriate selection of donors, dosage, concentration of neutralizing antibodies and times of transfusion. Therefore, at this time there is insufficient evidence to recommend for or against the use of CP as a treatment for COVID-19.

Original language	English (US)
Article number	100069
Journal	Journal of Translational Autoimmunity
Volume	3
DOIs	https://doi.org/10.1016/j.jtauto.2020.100069
State	Published - Jan 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Immunology
Immunology and Allergy

Access to Document

10.1016/j.jtauto.2020.100069

Cite this

@article{d94c71f28a64417dac3e3153a8fdfbed,

title = "Why will it never be known if convalescent plasma is effective for COVID-19",

abstract = "High expectations have been set around convalescent plasma (CP) for the treatment of COVID-19. However, none of the randomized controlled trials (RCTs) conducted so far have reached their primary endpoints. Herein we report that RCTs of CP disclose a high methodological variability in inclusion criteria, outcomes, appropriate selection of donors, dosage, concentration of neutralizing antibodies and times of transfusion. Therefore, at this time there is insufficient evidence to recommend for or against the use of CP as a treatment for COVID-19.",

author = "Manuel Rojas and Anaya, \{Juan Manuel\}",

note = "Funding Information: This work was supported by Universidad del Rosario (ABN-011), Bogota, Colombia. Publisher Copyright: {\textcopyright} 2020 The Authors Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",

year = "2020",

month = jan,

doi = "10.1016/j.jtauto.2020.100069",

language = "English (US)",

volume = "3",

journal = "Journal of Translational Autoimmunity",

issn = "2589-9090",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Why will it never be known if convalescent plasma is effective for COVID-19

AU - Rojas, Manuel

AU - Anaya, Juan Manuel

N1 - Funding Information: This work was supported by Universidad del Rosario (ABN-011), Bogota, Colombia. Publisher Copyright: © 2020 The Authors Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2020/1

Y1 - 2020/1

N2 - High expectations have been set around convalescent plasma (CP) for the treatment of COVID-19. However, none of the randomized controlled trials (RCTs) conducted so far have reached their primary endpoints. Herein we report that RCTs of CP disclose a high methodological variability in inclusion criteria, outcomes, appropriate selection of donors, dosage, concentration of neutralizing antibodies and times of transfusion. Therefore, at this time there is insufficient evidence to recommend for or against the use of CP as a treatment for COVID-19.

AB - High expectations have been set around convalescent plasma (CP) for the treatment of COVID-19. However, none of the randomized controlled trials (RCTs) conducted so far have reached their primary endpoints. Herein we report that RCTs of CP disclose a high methodological variability in inclusion criteria, outcomes, appropriate selection of donors, dosage, concentration of neutralizing antibodies and times of transfusion. Therefore, at this time there is insufficient evidence to recommend for or against the use of CP as a treatment for COVID-19.

UR - https://www.scopus.com/pages/publications/85096882919

UR - https://www.scopus.com/pages/publications/85096882919#tab=citedBy

U2 - 10.1016/j.jtauto.2020.100069

DO - 10.1016/j.jtauto.2020.100069

M3 - Review article

C2 - 33169114

AN - SCOPUS:85096882919

SN - 2589-9090

VL - 3

JO - Journal of Translational Autoimmunity

JF - Journal of Translational Autoimmunity

M1 - 100069

ER -

Why will it never be known if convalescent plasma is effective for COVID-19

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this